nach oben

Erschienen in:

01.07.2007

Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics

verfasst von: Benedikt Fischer, Eugenia Oviedo-Joekes, Peter Blanken, Christian Haasen, Jürgen Rehm, Martin T. Schechter, John Strang, Wim van den Brink

Erschienen in: Journal of Urban Health | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Since the initial Swiss heroin-assisted treatment (HAT) study conducted in the mid-1990s, several other jurisdictions in Europe and North America have implemented HAT trials. All of these studies embrace the same goal—investigating the utility of medical heroin prescribing for problematic opioid users—yet are distinct in various key details. This paper briefly reviews (initiated or completed) studies and their main parameters, including primary research objectives, design, target populations, outcome measures, current status and—where available—key results. We conclude this overview with some final observations on a decade of intensive HAT research in the jurisdictions examined, including the suggestion that there is a mounting onus on the realm of politics to translate the—largely positive—data from completed HAT science into corresponding policy and programming in order to expand effective treatment options for the high-risk population of illicit opioid users.

In alphabetical order of countries.

Hser Y, Hoffman V, Grella C, Anglin M. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58(5):503–508.PubMedCrossRef

Healey A, Knapp M, Marsden J, Gossop M, Stewart D. Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from a national prospective cohort survey. J Health Serv Res Policy. 2003;8(3):134–141.PubMedCrossRef

Adlaf E, Begin P, Sawka E. Canadian Addiction Survey (CAS). A National Survey of Canadians’ Use of Alcohol and Other Drugs: Prevalence of Use and Related Harms: A Detailed Report. Ottawa: Canadian Centre on Substance Abuse; 2005.

Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, NSDUH series H-30, DHHS Publication no. SMA 06-4194; 2006.

EMCDDA. Annual Report 2006: The State of the Drugs problem in Europe. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2006.

EMCDDA. Annual Report 2005: The State of the Drugs Problem in Europe. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2005.

The Office of National Drug Control Policy (ONDCP). Heroin Fact Sheet: June 2003. Available at: http://www.whitehousedrugpolicy.gov/publications/factsht/heroin/. Accessed November 8, 2006.

Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80(2):189–200.PubMed

Mark T, Woody G, Juday T, Kleber H. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61:195–206.PubMedCrossRef

10.

Wiessing L, Roy K, Sapinho D et al. Surveillance of Hepatitis C Infection Among Injecting Drug Users in the European Union. In: Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L, eds. EMCDDA Monographs: Hepatitis C and Injection Drug Use: Impact, Costs and Policy Options. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2004:91–135.

11.

Rehm J, Fischer B, Haydon E. Reducing the Risks, Harms and Costs of HIV/AIDS and Injection Drug Use: A Synthesis of the Evidence Base for Development of Policies and Programs. Background Paper #4. 2nd Annual Background Dialogue on HIV/AIDS. Warsaw: Health Canada/UNAIDS/Canadian International Development Agency; 2003.

12.

Wodak A. The current status of heroin prescription treatment for heroin dependence. Expert Opin Drug Saf. 2005;4(5):815–819.PubMedCrossRef

13.

Fischer B. Illegale Opiatsucht, Behandlung und ökonomische Kostenforschung—ein beispielhafter Überblick und eine Diskussion aus sozialwissenschaftlicher Perspektive [Illicit opioid dependence, treatment and economic cost research—a selective review and discussion from a social science perspective]. Sucht. 2003;4:2–7.CrossRef

14.

Fischer B, Rehm J, Kirst M et al. Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health. 2002;12:228–234.PubMedCrossRef

15.

Uchtenhagen A, Dobler-Mikola A, Steffen T, Gutzwiller F, Blattler R, Pfeiffer S. Prescription of Narcotics for Heroin Addicts: Main Results of the Swiss National Cohort Study. Medical Prescription of Narcotics, vol. 1. Basel: Karger; 1999.

16.

van den Brink W, Hendriks V, van Ree J. Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands. J Drug Issues. 1999;29(3):587–608.

17.

Stimson G, Metrebian N. Prescribing Heroin: What is the Evidence? York, England: Joseph Rowntree Foundation; 2003.

18.

Bammer G, van den BW, Gschwend P, Hendriks V, Rehm J. What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug Alcohol Rev. 2003;22(3):363–371.PubMedCrossRef

19.

Schechter MT. NAOMI—her time has come. North American Opiate Medication Initiative. J Urban Health. 2002;79(2):164–165.PubMed

20.

Schechter M et al. North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Refractory Injection Opiate Users. Canada: Canadian Institutes of Health Research; 2006.

21.

Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin assisted treatment for opioid dependence: a randomised, controlled trial. Br J Psychiatry. In press.

22.

Schulenburg J, Claes C. Gesundheitsokönomische Begleitforschung und Spezialstudie im Rahmen des bundesdeutschen Modellprojekts zur kontrollierten Heroinvergabe an Schwerstabhängige. Available at: http://www.heroinstudie.de/Gesundheitsoekonomie_Kurzf_abg.pdf; 2006.

23.

Bundesministerium fur Gesundheit. Pressemitteilungen zu Drogen und Sucht. Entscheidung zum Fortgang der diamorphingestützten Behandlung. Bundenministerium für Gesundheit. Pressemitteilungen zu Drogen und Sucht. 2006.

24.

van den Brink W, Hendriks V, Blanken P, Koeter M, van Zwieten B, van Ree J. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327(7410):310–315.PubMedCrossRef

25.

Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, Van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ. 2005;330(7503):1297.PubMedCrossRef

26.

March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31(2):203–211.PubMedCrossRef

27.

Colom J. Programa Catalán de Prescripción de Heroína Oral. Presentación en las II Jornadas Internacionales de heroína, Granada, 10–12 March 2005.

28.

Perneger T, Giner F, del Rio M, Mino A. Randomized trial of heroin maintenance programme for addicts who fail in conventional drug treatment. BMJ. 1998;317(7150):13–18.PubMed

29.

Frei A. Economic evaluation of the Swiss project on medically prescribed heroin substitution treatment. Psychiatr Prax. 2001;28(1):S41–S44.PubMedCrossRef

30.

Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001;358:1417–1420.PubMedCrossRef

31.

Frick U, Rehm J, Kovacic S, Ammann J, Uchtenhagen A. A prospective cohort study on orally administered heroin substitution for severely addicted opioid users. Addiction. 2006;101(11):1631–1639.PubMedCrossRef

32.

Ali R, Auriacombe M, Casas M et al. Report of the external panel on the evaluation of the Swiss Scientific Studies of Medically Prescribed Narcotics to Drug Addicts. Sucht. 1999;45(3):160–170.

33.

Farrell M, Hall W. The Swiss heroin trials: testing alternative approaches. BMJ. 1998;316(7132):639.PubMed

34.

Uchtenhagen A. Drug Law and Policy Reform in Switzerland: Briefing Paper for RSA Commission. Zurich: Research Institute for Public Health and Addiction; 2006.

35.

OFSP. Traitement avec prescription d’héroïne (HeGeBe) en 2004. Switzerland: Office Fédéral de la Santé Publique; 2005.

36.

Metrebian N, Carnwath Z, Mott J, Carnwath T, Stimson GV, Sell L. Patients receiving a prescription for diamorphine (heroin) in the United Kingdom. Drug Alcohol Rev. 2006;25(2):115–121.PubMedCrossRef

37.

Metrebian N, Carnwath T, Stimson GV, Storz T. Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction. 2002;97(9):1155–1161.PubMedCrossRef

38.

Strang J, Marsden J, Cummins M et al. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction. 2000;95(11):1631–1645.PubMedCrossRef

39.

Lintzeris N, Strang J, Metrebian N et al. Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct J. 2006;3(1):28.PubMedCrossRef

40.

Ferri M, Davoli M, Perucci CA. Heroin maintenance treatment for chronic heroin-dependent individuals: a Cochrane systematic review of effectiveness. J Subst Abuse Treat. 2006;30:63–72.PubMedCrossRef

41.

Rehm J, Fischer B. Heroingestütze Therapie für Opiatabhängige weder Allheilmittel noch Teufelswerk. Sucht. 2000;01(02):57–62.CrossRef

42.

Kahan M, Srivastava A, Shen K. Why we object to NAOMI. Heroin maintenance in Canada. Can Fam Physician. 2006;52:709–711.

43.

Guttinger F, Gschwend P, Schulte B, Rehm J, Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addict Res. 2003;9(2):73–79.PubMedCrossRef

44.

van den Brink W, Haasen C. Evidence based treatment of opioid dependent patients. Can J Psychiatry. 2006;51(10):635–646.PubMed

45.

Fischer B, Rehm J. Illicit opioid use and treatment for opioid dependence: challenges for Canada and Beyond. Can J Psychiatry. 2006;51(10):621–623.PubMed

46.

Fischer B, Rehm J, Patra J, Firestone Cruz M. Changes in illicit opioid use profiles across Canada. CMAJ. 2006;175(11):1–3.

47.

Wodak A. Public health and politics: the demise of the ACT heroin trial. Med J Aust. 1997;167:348–349.PubMed

Titel: Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics
verfasst von: Benedikt Fischer
Eugenia Oviedo-Joekes
Peter Blanken
Christian Haasen
Jürgen Rehm
Martin T. Schechter
John Strang
Wim van den Brink
Publikationsdatum: 01.07.2007
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Journal of Urban Health / Ausgabe 4/2007
Print ISSN: 1099-3460
Elektronische ISSN: 1468-2869
DOI: https://doi.org/10.1007/s11524-007-9198-y

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

Community Engagement in Urban Health Research

How Green is My City?

Exploring “Wine Shops” as a Venue for HIV Prevention Interventions in Urban India

Deprivation Indices, Population Health and Geography: An Evaluation of the Spatial Effectiveness of Indices at Multiple Scales

Indoor Environmental Differences between Inner City and Suburban Homes of Children with Asthma

Relationship Violence and Psychological Distress Among Low-income Urban Women